Clinical Trial Update: Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial update for SY-5007, a RET inhibitor, in RET-altered advanced solid tumors including non-small cell lung cancer and medullary thyroid c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• SY-5007 (SY-5007)

Snippet

Sponsor: Shouyao Holdings (Beijing) Co. LTD | Conditions: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1, Phase 2 | Status: UNKNOWN